21 related articles for article (PubMed ID: 36252396)
1. Design and biological evaluation of dual tubulin/HDAC inhibitors based on millepachine for treatment of prostate cancer.
Xie S; Leng J; Zhao S; Zhu L; Zhang M; Ning M; Zhao B; Kong L; Yin Y
Eur J Med Chem; 2024 Mar; 268():116301. PubMed ID: 38452727
[TBL] [Abstract][Full Text] [Related]
2. Flavone-based dual PARP-Tubulin inhibitor manifesting efficacy against endometrial cancer.
Sharma S; Chandra K; Naik A; Sharma A; Sharma R; Thakur A; Grewal AS; Dhingra AK; Banerjee A; Liou JP; Guru SK; Nepali K
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2276665. PubMed ID: 37919954
[TBL] [Abstract][Full Text] [Related]
3. Novel PIKfyve/Tubulin Dual-target Inhibitor as a Promising Therapeutic Strategy for B-cell Acute Lymphoblastic Leukemia.
Lu Z; Lai Q; Li ZF; Zhong MY; Jiang YL; Feng LY; Zha J; Yao JW; Li Y; Deng XM; Xu B
Curr Med Sci; 2024 Apr; 44(2):298-308. PubMed ID: 38619682
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and antitumor activity of dolutegravir derivatives bearing 1,2,3-triazole moieties.
Hou X; Mao L; Guo Y; Wang L; Peng L; Wang H; Yang J; Li S; Li YM
BMC Chem; 2024 May; 18(1):97. PubMed ID: 38715128
[TBL] [Abstract][Full Text] [Related]
5. Natural Products as Regulators against Matrix Metalloproteinases for the Treatment of Cancer.
Islam MT; Jang NH; Lee HJ
Biomedicines; 2024 Apr; 12(4):. PubMed ID: 38672151
[TBL] [Abstract][Full Text] [Related]
6. Recent Advances of Tubulin Inhibitors Targeting the Colchicine Binding Site for Cancer Therapy.
Hawash M
Biomolecules; 2022 Dec; 12(12):. PubMed ID: 36551271
[TBL] [Abstract][Full Text] [Related]
7. Novel combretastatin A-4 derivative containing aminophosphonates as dual inhibitors of tubulin and matrix metalloproteinases for lung cancer treatment.
Huang X; Chen Y; Zhong W; Liu Z; Zhang H; Zhang B; Wang H
Eur J Med Chem; 2022 Dec; 244():114817. PubMed ID: 36252396
[TBL] [Abstract][Full Text] [Related]
8. Dual-functional antitumor conjugates improving the anti-metastasis effect of combretastatin A4 by targeting tubulin polymerization and matrix metalloproteinases.
Yang L; Ma X; Guo K; Li J; Zhang C; Wu L
Eur J Med Chem; 2022 Aug; 238():114439. PubMed ID: 35551039
[TBL] [Abstract][Full Text] [Related]
9. A novel synthetic compound exerts effective anti-tumour activity in vivo via the inhibition of tubulin polymerisation in A549 cells.
Yan J; Pang Y; Sheng J; Wang Y; Chen J; Hu J; Huang L; Li X
Biochem Pharmacol; 2015 Sep; 97(1):51-61. PubMed ID: 26212540
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a Dual Tubulin and Neuropilin-1 (NRP1) Inhibitor with Potent In Vivo Anti-Tumor Activity via Pharmacophore-based Docking Screening, Structure Optimization, and Biological Evaluation.
Zheng L; Zou Y; Xie T; Wu X; Tan Y; Mei S; Geng Y; Chen S; Xu S; Niu MM
J Med Chem; 2023 Dec; 66(23):16187-16200. PubMed ID: 38093696
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of novel benzo[c]acridine-diones as potential anticancer agents and tubulin polymerization inhibitors.
Behbahani FS; Tabeshpour J; Mirzaei S; Golmakaniyoon S; Tayarani-Najaran Z; Ghasemi A; Ghodsi R
Arch Pharm (Weinheim); 2019 Jun; 352(6):e1800307. PubMed ID: 31012156
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of 1,2,3-triazole linked aminocombretastatin conjugates as mitochondrial mediated apoptosis inducers.
Kamal A; Shaik B; Nayak VL; Nagaraju B; Kapure JS; Shaheer Malik M; Shaik TB; Prasad B
Bioorg Med Chem; 2014 Oct; 22(19):5155-67. PubMed ID: 25192811
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
